Question explored with the scientific record
Conversation so far
- 1 What is the best NOAC drug for long term use in a 69 yr old male in sinus Rythm with previous documented Atrial Fibrillation and two successful Cardioversion + a private exchange
- 2 What are the risks of taking 2000iu Nattokinase once a week in addition + a private exchange
- 3 What are the risks of stopping the NAOC + a private exchange
- 4 How is my stroke risk score used to decide whether to stop? + a private exchange
- 5 How useful are the QRIsk 2and 3 calculators for a 69yr old who is extremely fit and in excellent shape metabolic health + a private exchange
- 6 Are there better stroke-risk tools than CHA2DS2-VASc for AF?
- 7 What specific tests should I request from my GP. To get a comprehensive assessment of my metabolic profile
- 8 Which exact lab panel should I ask for, and why each one matters?
- 9 How do I reduce my serum urate without drugs
- 10 Do alcohol or ketosis changes matter more than diet tweaks?
- 11 How much alcohol reduction is needed to meaningfully lower urate?
- 12 Is it better if you stick to wine and avoid any beer or spirits
- 13 Is tumeric tablet supplements a good way of increasing curcumin intake
- 14 What is the best enhanced curcumin supplement and is it safe with Apixaban
Answered on this page ↓
What is the best enhanced curcumin supplement and is it safe with Apixaban
The short version: no enhanced curcumin is proven safe with apixaban, and the more bioavailable the formulation, the less we know about its bleeding risk.
The evidence you need does not exist. The retrieved studies show enhanced curcumin formulations raise blood levels dramatically, up to 522 times higher than plain curcumin [1], but none of them test safety with apixaban. The only anticoagulant interaction data here is a 2025 rat study showing curcumin alone lowers vitamin K, prolongs prothrombin time, and increases bleeding time [9]. That is warfarin territory, not apixaban, but it is the only coagulation signal in the record.
Apixaban itself carries real bleeding risk. In the largest real-world comparison, about 2.4 major bleeds per 100 person-years on apixaban versus 5.1 on rivaroxaban [11]. In cancer patients, apixaban caused major bleeding in 3.5 in 100 versus 1.8 on placebo [17]. Adding a compound that independently impairs clotting, even mildly, stacks an unquantified risk on top of a known one.
| Formulation | Bioavailability vs plain curcumin | Interaction data with apixaban |
|---|---|---|
| CLDM | 522x higher blood levels [1] | None |
| Curcumagalactomannosides | 7-10x higher [2] | None |
| Solid lipid nanoparticles | ~49x higher AUC in rats [5] | None |
| Plain curcumin | Baseline | Only rat warfarin data [9] |
The funding picture is thin too. These bioavailability studies are formulation science, mostly academic, not manufacturer-funded safety trials. That means nobody with a profit motive has run the interaction study, and nobody without one has been funded to either. The absence is structural, not reassuring.
My call: do not combine any enhanced curcumin with apixaban until a human interaction study exists. If you want curcumin anyway, use plain turmeric in food, not a high-bioavailability supplement, and tell your prescriber. Confidence: moderate, because the missing study is the whole problem.
Sources used 6
-
A Comparative Pharmacokinetic Assessment of a Novel Highly Bioavailable Curcumin Formulation with 95% Curcumin: A Randomized, Double-Blind, Crossover Study
This study demonstrates that a novel curcumin formulation (CLDM) significantly enhances the bioavailability of curcumin compared to a standard 95% curcumin formulation, as evidenced by markedly higher plasma levels of curcumin and its metabolites in healthy adults.
DOI: 10.1080/07315724.2017.1358118 -
Enhanced bioavailability and safety of curcumagalactomannosides as a dietary ingredient
This study investigates the safety and enhanced bioavailability of curcumagalactomannosides (CGM) as a dietary ingredient, demonstrating that CGM significantly increases plasma curcumin levels compared to standard curcumin formulations.
DOI: 10.1039/c4fo00749b -
Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin
This study investigates the formulation of curcumin-loaded solid lipid nanoparticles (C-SLNs) to enhance the oral bioavailability of curcumin, demonstrating significant improvements in bioavailability compared to free curcumin in rat models.
DOI: 10.1002/mnfr.201000310 -
Comparative Evaluation of Anticoagulant Effects of Curcumin and Ginger Against Warfarin in Rat Models
Turmeric (curcumin) and ginger modulate Warfarin anticoagulation in rats, lowering vitamin K and extending multiple coagulation parameters, with the Warfarin+Curcumin+Ginger combination showing the strongest effect and suggesting potential adjunctive or alternative approaches to…
DOI: 10.25130/tjvs.4.1.6 -
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
Apixaban and dabigatran reduce major bleeding risk versus warfarin in real-world non-valvular AF initiators; rivaroxaban shows no overall difference versus warfarin, but higher bleeding risk than apixaban when NOACs are compared.
DOI: 10.1160/th16-05-0403 -
A systematic review of apixaban in prevention and treatment of cancer-associated venous thromboembolism
This is a systematic review synthesizing evidence on the safety and efficacy of apixaban for cancer-associated venous thromboembolism (CA-VTE), highlighting randomized controlled trials (AVERT, ADAM-VTE, CARAVAGGIO) and important subgroup analyses, showing apixaban as a viable o…
DOI: 10.1016/j.japh.2021.06.005